O utcome measures vary between trials, particularly in the field of cardiac surgery, for which there is currently no widely accepted standard for reporting postoperative adverse events. The lack of uniformity has hindered the ability to compare and synthesize findings across different trials. Efforts to perform meta-analyses in cardiac surgery have often been impeded by the heterogeneity of pooled outcomes. Furthermore, generic composite outcomes traditionally used in cardiology such as major adverse cardiac events (MACE; death, myocardial infarction [MI] with or without revascularization) and major adverse cardiovascular and cerebrovascular events, or MACCE (death, MI, stroke), are neither designed nor adapted for cardiac surgery because they do not reflect other important postsurgical complications. The Society of Thoracic Surgeons (STS) has provided definitions of postsurgical complications and a surgery-specific composite outcome consisting of in-hospital death, stroke, prolonged ventilation, acute kidney injury, deep sternal wound infection, or reoperation 1 ; however, the extent to which this composite outcome has been adopted for use in clinical trials is unknown. The appropriateness of combining adverse events with differing clinical impacts (eg, stroke and wound infection) has also been questioned. 2 There is a pressing need to improve and homogenize outcome reporting in cardiac surgery, similar to what was successfully achieved in other fields such as the RIFLE classification 3 , the Bleeding Academic Research Consortium 4 and the Transcatheter Valve Academic Research Consortium (VARC). 5 The objective of this paper was to review the selection and definition of individual and composite outcomes reported in the recent body of randomized controlled trials in cardiac surgery. With this knowledge, stakeholders would be better equipped to develop recommendations for standardized outcome reporting adapted to cardiac surgery.
Methods

Search Strategy
The PubMed search string "Cardiac Surgical Procedures" (MeSH) AND "Randomized Controlled Trial" (Publication Type) was used to identify cardiac surgery randomized controlled trials published between January 
Selection Criteria
Studies were included if the study design was randomized and the study population was undergoing coronary artery bypass grafting and/or heart valve repair or replacement surgery. Studies were excluded if the primary outcome was not a clinical event (eg, the primary outcome was a biomarker) or if the study population was pediatric or focused on congenital heart disease. Case reports, case series, editorials, reviews, and post hoc analyses of randomized controlled trial data were also excluded.
Data Extraction
For each article meeting inclusion criteria, the following variables were extracted: first author, journal, year of publication, trial name and registration, sample size, study population, intervention, control, primary outcomes, secondary outcomes, and duration of follow-up. In addition, the operational definitions used to ascertain MI, stroke, prolonged ventilation, acute renal injury, and bleeding were extracted. Patient-centered outcomes included postoperative pain, quality of life, mood, neurocognitive function, and New York Heart Association functional class. Health care resource utilization included hospital and intensive care unit length of stay and cost analyses.
Analysis
Studies were reviewed, and data were extracted in duplicate by 2 independent observers (M.G., L.D.); disagreements were resolved by consensus. The primary and secondary outcomes were represented in tabular format and summarized according to the number and proportion of randomized controlled trials reporting each outcome measure. The Stata 13 software package (StataCorp) was used to organize the extracted data and to prepare summary statistics.
Results
Of 190 potentially relevant trials, 34 met the selection criteria and were included in our systematic review (Figure) . Included trials were evenly distributed among the journals searched ( Mortality (all-cause and/or cardiovascular) was reported as an individual end point or as part of a composite end point in 28 trials (82%), MI was reported in 23 trials (68%), need for repeat revascularization or reoperation was reported in 22 trials (65%), stroke or transient ischemic attack was reported in 18 trials (53%), acute kidney injury was reported in 11 trials (32%), and bleeding complications were reported in 8 trials (24%) ( Table 2 ). Patient-centered outcomes were reported in 10 trials (29%). Health care resource utilization was reported in 12 trials (35%).
Composite end points were used as the primary outcome measure in 19 trials and as a secondary outcome measure in 4 trials. Overall, 14 different composite end points were used, of which 6 were variants of the MACCE composite, 3 were variants of the MACE composite, and none were based on the STS composite. Eight of 9 trials using the MACE or MACCE composite incorporated repeated revascularization procedures.
The operational definitions of individual end points were equally variable. MI was defined based on World Health Organization criteria in 2 studies, European Society of Cardiology and/or American Heart Association criteria in 4 studies, VARC criteria in 1 study, creatinine kinase elevation greater than the upper limit of normal in 2 studies, creatinine kinase or troponin elevation >3 times the upper limit of normal in 1 study, creatinine kinase or troponin elevation >5 times the upper limit of normal in 4 studies, and creatinine kinase or troponin rise to various levels depending on time after surgery in 3 studies. No diagnostic criteria for MI were provided in 5 trials.
Stroke was defined based on focal neurological deficit with imaging findings in 3 trials and on acute focal neurological deficit lasting ≥24 hours with or without confirmatory imaging in 11 trials; no diagnostic criteria were provided in 6 trials.
Acute kidney injury was defined based on need for renal replacement therapy in 5 trials, need for renal replacement therapy or prespecified elevation in creatinine (each with different thresholds, ranging from 221 mmol/L [2.5 mg/dL] to 309 mmol/L [3.5 mg/dL]) in 3 trials, and prespecified elevation of twice the preoperative creatinine level with or without oliguria in 2 trials; no diagnostic criteria were provided in 2 trials. Prolonged ventilation or intubation was defined as >24 hours in 2 trials and >48 hours in 1 trial. The definition of postoperative bleeding differed in each of the 8 trials in which it was reported.
Discussion
To our knowledge, this review of adult cardiac surgery trials is the first to examine the current state of outcome reporting. We found that mortality and MI were most frequently reported as individual or composite end points and, conversely, that the STS composite was not used as an outcome measure. One of the most striking findings was the heterogeneity of composite end point reporting. This was apparent at 3 different levels. First, the decision to use or not use a composite as the primary outcome measure was evenly split between trials. Second, the choice of events included in composites was highly variable. Third, the operational definitions of events were ill defined, particularly the thresholds used to dichotomize continuous metrics such as troponin rise for MI or ventilation duration. MACE and MACCE also had varied definitions in the trials, similar to prior reports in general cardiology. 7 Heterogeneity in cardiac surgery outcome reporting limits the ability to synthesize and meta-analyze results across trials to generate guidelines with the highest level of evidence. 8 This is relevant, given the shift toward evidence-based practice derived from randomized controlled trials in cardiac surgery and other surgical subspecialties. 9 In addition, nonstandardized outcome measures limit the ability to directly compare the effectiveness of various surgical techniques, perioperative interventions, and providers. 10 As new competing techniques and technologies emerge, it is increasingly important that surgical outcome reporting be comparable among trials. Due to the lack of consensus outcome measures in cardiac surgery, investigators often default to using mortality as the end point of choice, despite being grossly underpowered to do so (as was apparent in the many of the trials reviewed and in an even greater proportion of observational studies). Similarly, with the exception of the STS models, most risk scores use mortality as the sole end point, neglecting the importance of other complications and patientcentered outcomes. The use of composite end points in cardiac surgery may be beneficial for several reasons. Composite end points avoid the arbitrary choice of a single outcome when several may be of clinical importance for the cardiac surgery patient 45 and allow for estimation of the net clinical benefit of the intervention Quality of life, physical performance, cognitive function, and dependency for activities of daily living have been broadly categorized as patient-centered outcomes because they reflect domains that are crucial to the patient but are extrinsic to traditional domains of mortality and pathophysiology that are emphasized by physicians and researchers. There is increasing awareness in the cardiovascular community that these data should be collected and reported, particularly when studying elderly populations in which the priority of care may have shifted from longevity to quality of life. Postoperative length of stay, stroke, and readmission have been identified as important indicators of quality of care, 53 strengthening the rationale for also reporting these end points. 54 For a criterion to be a useful part of a composite end point, it should be clinically important and reliably ascertainable. In the cardiology literature, consensus efforts have been made to standardize adjudication of MI, 55, 56 renal injury, 3 and bleeding. 4 These consensus documents are not necessarily portable to the specific context of cardiac surgery, for which the mechanism, magnitude, and clinical implication of certain events are fundamentally different. Consider the difference between medical versus surgical bleeding and ambulatory versus perioperative troponin rise. The STS composite does not include perioperative MI, which is in part due to its low ascertainment reliability. 1 Recommended definitions of perioperative MI vary considerably, from a highly restrictive approach requiring evidence of an acute coronary embolus 57 to a multifaceted approach incorporating clinical and biomarker criteria. 55 Other potentially important cardiac surgery outcomes, such as prolonged postoperative mechanical ventilation, have not been uniformly defined or adopted for use. VARC is a context-specific consensus document focused on transcatheter aortic valve replacement; it provides standardized end points with clearly defined criteria for reporting. 5 A meta-analysis showed that the VARC end points were frequently being implemented to report clinical outcomes. 58 Although there has been an initial attempt to develop a similar document focused on pediatric cardiac surgery, 59 there has yet to be an attempt in adult cardiac surgery.
Limitations
Because our search was limited to 5 scientific journals (for feasibility purposes), we did not capture trials published in other journals. The selected journals represent the highest ranked impact factors in their respective subspecialties of cardiothoracic surgery, cardiology, and general medicine, and we expect that the heterogeneity of outcome reporting could have been more pronounced if we had included smaller lower ranked studies. Conversely, the selected trials encompassed a wide variety of interventions and comparators (surgery versus surgery, surgery versus transcatheter procedure, surgery plus adjunctive medical therapy versus surgery alone), such that the heterogeneity of outcome reporting could have been less pronounced if we restricted our selection criteria to one of these types of trials. We excluded trials that did not report a clinically driven primary outcome, and this also led to underrepresentation of smaller studies that were underpowered to assess clinical events. We chose to focus on clinical events because these will likely form the basis of future efforts to develop standardized guidelines for reporting outcomes.
Conclusion
Outcome reporting in the cardiac surgery literature is heterogeneous, and efforts should be made to standardize the outcomes reported and the definitions used to ascertain them. Measures of functional status and resource utilization are currently underreported and should be integrated in standardized reporting schema. The development of standardizing outcome reporting is an essential step toward strengthening the process of evidence-based care in cardiac surgery.
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